Pfizer has signed a deal to allow other manufacturers to make its experimental COVID-19 pill, possibly opening up access to treatment to countries across the world.

On Tuesday, the company said it would give a license for the pill to the Medicines Patent Pool, a U.N.-backed group based in Geneva, Switzerland. The agreement would allow generic drug companies to produce the pill for use in 95 countries, which would cover about 53% of the world's population, according to a news release.